Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorPozo Rosich, Patricia
dc.contributor.authorLucas, Christian
dc.contributor.authorWatson, David P. B.
dc.contributor.authorGaul, Charly
dc.contributor.authorRamsden, Emma
dc.contributor.authorRitter, Shannon
dc.date.accessioned2022-05-02T11:55:49Z
dc.date.available2022-05-02T11:55:49Z
dc.date.issued2021-12
dc.identifier.citationPozo-Rosich P, Lucas C, Watson DPB, Gaul C, Ramsden E, Ritter S, et al. Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. Pain Ther. 2021 Dec;10:1691–1708.
dc.identifier.issn2193-651X
dc.identifier.urihttp://hdl.handle.net/11351/7417
dc.descriptionMigraine; Treatment failure; Work productivity
dc.description.abstractIntroduction Migraine is consistently ranked as one of the most disabling neurological conditions in the world, often causing a substantial impairment of daily activities and quality of life. It also carries a high economic burden of direct and indirect healthcare costs. Patients with difficult-to-treat migraine often cycle through different preventive therapies, but real-world prospective evidence describing the burden of migraine in patients with prior preventive treatment failure (PPTF) in Europe is limited. In BECOME, we aimed to characterize and assess the prevalence and burden of migraine in patients with PPTF attending specialist headache centers in Europe and Israel. Furthermore, we assessed this burden in pre-specified subgroups based on the frequency of monthly migraine days (MMD) and number of PPTFs. Methods BECOME was a prospective, non-interventional study conducted in two concurrent parts across 17 countries in Europe and Israel. In part 1, patients visiting the centers over a 3-month period were screened for frequency of PPTF, MMD, and other characteristics. In part 2, patients from part 1 with ≥ 1 PPTF and ≥ 4 MMD were enrolled, and impact of migraine on patient-reported outcomes, and healthcare resource utilization (HRU) were examined. Results In part 1 (n = 20,837), 62.2% of patients reported ≥ 1 PPTF. In part 2 (n = 2419), 15.3% of patients reported ≥ 4 PPTF. In part 2, the migraine burden measured by the EuroQoL 5 dimensions 5 level (EQ-5D-5L) questionnaire indicated an impact of at least moderate severity in performing usual activities in 26.5% of patients, pain/discomfort in 51.2%, and 26.1% reported being at least moderately anxious/depressed. Most patients reported a severe impact on daily activities and disability due to migraine. Abnormal Hospital Anxiety and Depression subscale scores of ≥ 11 were observed in 29% (anxiety) and 19.8% (depression) of the population. In part 2, analysis of HRU showed 21.2% patients visited an emergency department and 8.4% were hospitalized for headache/migraine in the past year. Conclusions This study provides real-world evidence of the high personal, social, and HRU burden of migraine in Europe and Israel.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesPain and Therapy;10
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectMigranya - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshMigraine Disorders
dc.subject.mesh/drug therapy
dc.subject.meshTreatment Failure
dc.titleBurden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s40122-021-00331-3
dc.subject.decstrastornos migrañosos
dc.subject.decs/farmacoterapia
dc.subject.decsfracaso del tratamiento
dc.relation.publishversionhttps://doi.org/10.1007/s40122-021-00331-3
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Pozo-Rosich P] Unitat de Cefalees, Servei de Neurologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Grup de Recerca en Cefalees i Dolors Neurològics, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Barcelona, Spain. [Lucas C] Pain Clinic, Service de Neurochirurgie, Hôpital Salengro, CHU de Lille, 59037 Lille Cedex, France. [Watson DPB] Hamilton Medical Group, Aberdeen AB15 4ZT, Scotland. [Gaul C] Migraine and Headache Clinic Königstein, 61462 Königstein im Taunus, Germany. [Ramsden E] Novartis Pharma AG, 4033 Basel, Switzerland. [Ritter S] Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
dc.identifier.pmid34643891
dc.identifier.wos000706941200001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record